In this episode, Phil Katz and Jim Johnson continue their conversation about the impact of COVID-19 on FDA’s drug inspection program and the steps com...View Details

In this episode, Phil Katz, David Horowitz and Jim Johnson explore the impact on industry and FDA of the agency’s decision to halt foreign inspections...View Details

In this episode, Michael S. Heyl and Jonathan S. Kahan explore questions around FDA’s Emergency Use Authorization authorities, how it has been used hi...View Details

In this episode, Arne Thiermann and Mike Druckman explore questions around the supply chain in the life sciences and health care industry. They highli...View Details

Looking Ahead

In today’s episode, we’ll visit with Hogan Lovells partners, Greg Noonan (Boston) and Michele Sartori (Washington, D.C.), as they discuss the False Cl...View Details

Ivan Zapien, partner and practice leader of the Government Relations and Public Affairs (GRPA) practice, focuses his podcast on the issues, people, an...View Details

In today’s episode, we’ll visit with Hogan Lovells counsel, Chava Brandriss and senior associate Ashley Hutto-Schultz, both from our Washington D.C. o...View Details

In today’s episode, we’ll visit with Hogan Lovells partner Mike Vernick and senior associate Mike Scheimer, both from our Washington, D.C. office, as ...View Details

In this episode, Jörg Schickert, one of the leading life sciences and health care lawyers for regulatory and commercial issues in Europe, is going to ...View Details

In this episode, Hogan Lovells partner Mike Theis, and associate Clara Troyer, both from the Denver office, will be discussing Lessons learned from Po...View Details

Older Episodes »